Active Filter(s):
Details:
Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: Fexuclue
Highest Development Status: Approved Product Type: Small molecule
Recipient: Daewoong Pharmaceutical
Deal Size: $20.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2023